A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
about
Treatment for Lambert-Eaton myasthenic syndromeTreatment for Lambert-Eaton myasthenic syndromeTreatment for Lambert-Eaton myasthenic syndromeAminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunitCalcium-activated potassium channel SK1- and IK1-like immunoreactivity in injured human sensory neurones and its regulation by neurotrophic factorsParaneoplastic syndromes associated with lung cancerParaneoplastic syndromes of the spinal cord, nerve, and muscle.Paraneoplastic syndromes: an approach to diagnosis and treatment.Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridineSynaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxiasVoltage gated calcium channel antibody-related neurological diseasesLambert-eaton myasthenic syndrome: diagnosis and treatment.Electrodiagnostic studies in the management and prognosis of neuromuscular disorders.Neurologic complications of non-Hodgkin's lymphoma.IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.The European LEMS Registry: Baseline Demographics and Treatment ApproachesSuccessful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.Treatment in Lambert-Eaton myasthenic syndrome.Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton MyastheniaReview of the Diagnostic Challenges of Lambert-Eaton Syndrome Revealed Through Three Case Reports.Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.The Effects of K(+) Channel Blockade on Eccentric and Isotonic Twitch and Fatiguing Contractions in situ4-aminopyridine improves lower urinary tract symptoms in a patient with benign prostatic hyperplasia and downbeat nystagmus syndrome.Five years experience on 3,4-diaminopyridine phosphate in Lambert-Eaton syndrome: Case reports.Hypotension due to Chemotherapy in a Patient with Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome Undergoing Hemodialysis: A First Case Report.Treatment of paraneoplastic neurologic disorders.Improvement of diaphragm and limb muscle isotonic contractile performance by K+ channel blockade.3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation.Voltage-dependent potassium currents during fast spikes of rat cerebellar Purkinje neurons: inhibition by BDS-I toxin.3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.Content variability of active drug substance in compounded oral 3,4-diaminopyridine products.
P2860
Q24234103-63E31762-87DF-401E-B7AD-593C105DBE53Q24246913-0D35CD0B-4120-45F7-8C6A-0243A485A3C6Q24248823-620372D3-3397-4ED2-AEB1-7AC0BDA1B4ECQ24657140-069D6634-3918-45CE-A93F-BB6EF736CBA4Q29030863-47452537-D4F8-4572-B2F0-E03EA24B5C74Q34023610-BC32B1BE-AF61-479B-B692-38D600D453D7Q34096509-CBB35F85-4268-4C00-AFB1-46E5071C6DC4Q34135478-EEA6F014-3BAC-4C4B-93BC-4A729187A4E3Q34206472-2677FAFE-E06F-4A3F-9817-6A526D623C08Q34437216-E3CA48D9-305D-4F43-803A-499CE61AC497Q35049590-F2A2C9E6-A74A-4EBD-BB72-800C5FDA59D9Q35104451-F21B2767-3229-44FE-A6D1-38C87831B25BQ35179343-763858E5-1F7B-4051-A847-65CB4B921899Q35573400-C8DCBEB6-82FD-477C-B502-67523243EA91Q35645263-E6829E64-F774-4A83-89FB-7846E1CC67CBQ35989738-2A611734-EEC2-44C7-B527-8AD6F425A054Q36164823-ADB107FA-2905-46E8-BB44-D227F4528212Q36389693-61CEADEF-D613-439B-B9EF-E72F510EB869Q36640458-6AC38375-3788-469A-8317-978DA7AC9A0CQ37803410-27725544-7FD9-4C0F-9356-D3B8419ECEC5Q38070758-C2568A20-0CB1-49B2-AD46-5C6EA1F4D59AQ38721390-510BC1EF-9633-4784-8C7A-2172AB7ADCC8Q38895764-1A32D90C-0819-49CF-B3DC-AD09DEBA3884Q39083085-793EE086-E539-4B32-878B-07847998CD0AQ39293213-09BDC8B1-676F-42DB-A050-BBF811DB4BE6Q40350903-DF8C3E4E-E560-45C9-86BD-AA33024C40B6Q41820595-EF7CD557-D310-49A9-BD87-795CB06A02D3Q42061637-04B18A0D-7AA8-4420-BD26-1D39CB6DFC11Q42090297-1BFF845A-C81E-4889-9BFC-EE55E92892E5Q42581091-491CE975-F908-488D-A6AE-EA928A4F63F7Q42907014-4C03D309-CF29-4ED9-90AD-9492414549BCQ42917344-A0915460-280B-45B5-B1EB-16B2E53D338AQ43282674-743F88A8-6D31-454A-939D-D6FE12698446Q45023480-F018EF60-224C-4C1B-B203-CCB366F555B6Q46055747-082083C7-5B2A-4DB9-8630-734BA24C99ACQ46240367-D6CB9C31-D144-42DA-9015-B71915FB7DE0Q48387602-40E0FCE6-A029-4FA9-94F3-41EB4B276FCAQ49561997-7D726FC4-CCDD-4F71-B7A5-3B1032D69CCBQ50073063-232423BD-48AC-4BA7-8CE5-AA226DE5B3F3Q50522609-2F94AD5B-49EE-4F0B-9236-1759FB523203
P2860
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
@en
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
@nl
type
label
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
@en
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
@nl
prefLabel
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
@en
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
@nl
P2093
P356
P1433
P1476
A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
@en
P2093
Edwards LJ
Sanders DB
Sanders LL
P304
P356
10.1212/WNL.54.3.603
P407
P577
2000-02-01T00:00:00Z